Status:

TERMINATED

Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity

Lead Sponsor:

PathMaker Neurosystems Inc.

Collaborating Sponsors:

Spaulding Rehabilitation Hospital

National Institute of Neurological Disorders and Stroke (NINDS)

Conditions:

Muscle Spasticity

Stroke

Eligibility:

All Genders

18-85 years

Phase:

NA

Brief Summary

This is a multi-center, randomized, double-blind (patient and evaluator), sham-controlled study to be conducted in stroke patients with upper-extremity spasticity. The main objectives of this study ar...

Detailed Description

Stroke is the fifth leading cause of death in the U.S. and a leading cause of serious long-term disability. There are over 7.5 million patients in the U.S. living with stroke, and an estimated 795,000...

Eligibility Criteria

Inclusion

  • ≥ 18 to \< 85 years of age
  • First single focal unilateral hemisphere lesion with diagnosis verified by brain imaging (MRI or CT scans) that occurred at least 6 months prior to study enrollment
  • At least 6 weeks of stable UE spasticity symptoms (as confirmed by medical history) with a baseline Modified Ashworth Scale (MAS) score of 1+ to 3 (on the 0, 1, 1+, 2, 3, 4 scale), inclusive, in the wrist flexor muscles
  • Willing to forgo botulinum toxin, phenol or alcohol injections into the muscles of the limb targeted for the study treatment; intrathecal baclofen; digitalis, and morphine for the subject's duration in the study
  • Willing to forgo upper extremity physical and occupational therapy for the duration of the study (lower extremity PT and OT are allowed)
  • Willing to maintain current regiment for oral spasticity medication(s) and neurotransmitter medication(s) for the subject's duration in the study
  • Cognitive function sufficient to understand the experiments and follow instructions (per interview with appropriate clinician)

Exclusion

  • Fixed contractures or profound muscle atrophy of the target spastic wrist to be treated
  • Change in antispastic oral medication (baclofen, clonidine, benzodiazepine, dantrolene, gabapentin, tizanidine) in the 2 months prior to study enrollment
  • Use of digitalis, morphine, or intrathecal pump in the week prior to study enrollment
  • Prior botulinum toxin injection(s) into the muscles of the limb targeted for the study treatment within 12 weeks of study enrollment
  • Prior phenol or alcohol injections into the muscles of the limb targeted for the study treatment within 6 months of study enrollment
  • Prior surgery for spasticity in the target muscle group
  • Prior transcranial or trans-spinal direct current stimulation for any reason
  • Presence of potential tsDCS risk factors:
  • Damaged skin at the stimulation sites (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.)
  • Lack of sensory perception at the stimulation sites
  • Presence of an electrically, magnetically, or mechanically activated implant (including cardiac pacemaker) or any other electrically sensitive support system with the exception of loop recorders
  • Ferrous metal in the path of the current flow (jewelry must be removed during stimulation)
  • Past history of epileptic seizures or unexplained spells of loss of consciousness during the previous 36 months
  • Other neurological conditions involving CNS impairment, including Parkinson's Disease, Multiple Sclerosis, and Spinal Cord Injury
  • Any medical condition that would prevent the subject from being able to participate in the clinical outcome measures
  • Previous participating in a study involving the application of tsDCS
  • Pregnancy in women (as determined by pregnancy test in pre-menopausal women)

Key Trial Info

Start Date :

March 4 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2024

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT04742257

Start Date

March 4 2022

End Date

June 30 2024

Last Update

August 15 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Spaulding Rehabilitation Hospital

Cambridge, Massachusetts, United States, 02138

2

Spaulding Rehabilitation Hospital

Charlestown, Massachusetts, United States, 02114